Navigation Links
FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
Date:3/1/2011

SILVER SPRING, Md., March 1, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups (exacerbations) or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD).

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)  

COPD is a serious lung disease that makes breathing difficult. Symptoms can include breathlessness, chronic cough, and excessive phlegm. An exacerbation can last up to several weeks and result in lung function decline, increased risk of death, and may be associated with severe anxiety.

Cigarette smoking is the leading cause of COPD, according to the National Heart, Lung, and Blood Institute. COPD is the fourth leading cause of death in the United States.

Roflumilast, a new drug class for the treatment of COPD, is an inhibitor of an enzyme called phosphodiesterase type 4 (PDE-4). It is indicated for people with severe COPD to treat the symptoms of cough and excess mucus linked to bronchitis. Roflumilast is not intended to treat another form of COPD which involves primary emphysema.

"COPD is a serious disease that gets worse over time," said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research. "New treatment options that reduce frequency of flare-ups or exacerbations are important in helping patients with COPD associated with chronic bronchitis and a history of exacerbations in managing this debilitating disease."

The safety and effectiveness of roflumilast was demonstrated in two Phase 3 clinical studies that included more than 1,500 patients ages 40 and older who received roflumilast. Those treated had a history of COPD associated with chronic bronchitis and had experienced an exacerbation of the disease during the 12 months prior to be
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... VILLAGE, Nev. , July 28, 2014 PDL ... that the Company will release its second quarter 2014 financial ... August 11, 2014, after market close. PDL,s management will host ... Eastern Time to discuss the financial results.  A slide presentation ... link on the PDL website. Conference Call Details ...
(Date:7/28/2014)... 28, 2014  ProteinSimple announced today that it has ... new assay allows users to detect all proteins separated ... Western users can analyze proteins without the need for ... changed protein analysis as we know it today. First, the ... - no messy gels, no transfer tanks, no blots, ...
(Date:7/28/2014)... HILDEN , Germany and ... -- , Collaboration aims to ... plasma samples to guide the use of IRESSA  for ... test will build on QIAGEN,s FDA-approved  therascreen   EGFR test ... QIAsymphony family of automated instruments  Project enabled ...
Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2ProteinSimple Says "Never Run a Gel Again!" 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
... The non-profit Midwest Business Group on Health (MBGH) ... national organizations, have launched a health awareness campaign combining the ... people improve and manage health conditions. The Take Control ... will run through the end of the year and into ...
... NATICK, Mass., Oct. 28 Boston Scientific Corporation (NYSE: ... a definitive agreement under which Stryker Corporation will acquire ... billion, payable in cash, of which $1.4 billion is ... following the closing and upon the occurrence of the ...
Cached Medicine Technology:New 'Take Control of Your Health' Education Series to Improve Health of Chicagoans 2Boston Scientific Agrees to Sell Neurovascular Business to Stryker 2Boston Scientific Agrees to Sell Neurovascular Business to Stryker 3Boston Scientific Agrees to Sell Neurovascular Business to Stryker 4
(Date:7/28/2014)... (PRWEB) July 28, 2014 Irresistible infants have met ... Spoonful of Comfort. The online gifting company specializes in homemade chicken ... , The New Baby package starts with home-from-the-hospital essentials every new ... , 6 rolls , 6 cookies , ... , The soup is ready to heat and eat upon delivery, ...
(Date:7/28/2014)... July 28, 2014 According to a ... Solution Software Market- Global Industry Analysis, Size, Share, Growth, ... device market was valued at USD 3,005 million in ... of 13.8% from 2014 to 2020, to reach an ... Globally, the e-clinical solution software market is witnessing significant ...
(Date:7/28/2014)... Carolina State University is proposing a new theory to ... age, but don,t necessarily show declines in the workplace ... motivated older adults are to maintain focus on cognitive ... explain the difference we see in cognitive performance in ... psychology at NC State and author of a paper ...
(Date:7/28/2014)... Alta Resources , a global ... Fortune 500 brands, announced today that it plans to ... Wisconsin, California, Florida and the Philippines. More than 700 ... campus. , A majority of the hiring is to ... require additional staffing in preparation for the Annual Enrollment ...
(Date:7/28/2014)... July 28, 2014 Termed by the ... abuse causes more fatal overdoses than heroin and cocaine ... (1) Those who are particularly vulnerable to succumbing to ... up), with many in this age group taking at ... growing epidemic was reawakened in the White House in ...
Breaking Medicine News(10 mins):Health News:Spoonful of Comfort Announces "New Baby" Gift Package 2Health News:Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Motivation explains disconnect between testing and real-life functioning for seniors 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 3Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 2Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 3Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 4
... IRVINE, Calif., Nov. 3 Endologix, Inc. (Nasdaq: ELGX ), ... John McDermott, President and Chief Executive Officer, is scheduled to present ... at the Canaccord Adams 3rd Annual Cardiovascular Conference at the Nikko ... Event: Canaccord Adams 3rd Annual Cardiovascular ...
... the same holds true for humans, researchers say , TUESDAY, Nov. ... sweet life may also be the short life. , New research ... 20 percent of their life span. , It,s unclear what ... impact of diets high in sugar, according to the study authors, ...
... is also a prescription for self-esteem among breast cancer ... Medicine research. Breast cancer survivors who lift weights regularly ... more satisfied with their intimate relationships compared with survivors ... study published in the journal Breast Cancer Research ...
... ... in Jackson, Miss. has started posting surgical videos as part of a new section ... surgery to correct sunken chest syndrome in pediatric patients. As part the new portion ... unique procedure by way of video. , ...
... 3 Triple-S Management Corporation (NYSE: GTS ), the ... revenues of $507.3 million and operating income of $15.4 million ... of $18.1 million, or $0.62 per diluted share, includes an ... share, in net realized and unrealized gains on investments and ...
... claims and risk management provider Avizent announced today the introduction ... medical experts are involved in workers, compensation claims from day ... the new service is to safely return injured employees to ... workers, comp claims. Avizent is one of only a few ...
Cached Medicine News:Health News:Endologix to Present at Three Upcoming Conferences 2Health News:Sugar Shortens Life Span in Worms 2Health News:Weight training boosts breast cancer survivors' body image and intimate relationship satisfaction 2Health News:New Video Post Shows Minimally Invasive Procedure To Correct Sunken Chest Syndrome 2Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 2Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 3Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 4Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 5Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 6Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 7Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 8Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 9Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 10Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 11Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 12Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 13Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 14Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 15Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 16Health News:Avizent's New TeamCOMP Approach Helps Ensure Lower Workers' Comp Costs and Faster Claims Resolution 2
... two perforations which enable procedure-specific ... single or bilateral configurations to ... has two perforations which enable ... various single or bilateral configurations ...
Unique 2 in 1 design allows simultaneous absorption of excess fluid & protection of flap & hinge, Lint-free PVAmaterial....
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Dome shape, extra smooth tip provides safe insertion through wound & manipulation within the eye. 45, 4.0mm from end...
Medicine Products: